Sunshine Biopharma (SBFM) EBT Margin (2015 - 2026)
Sunshine Biopharma's (SBFM) quarterly EBT Margin came in at 16.88% in Q2 2026, up 416.0% on a YoY basis from 3.27% in Q2 2025, and down 9.79% quarter-over-quarter from 15.38% in Q1 2026.
Powered by 
Analysis
Sunshine Biopharma (SBFM) EBT Margin (2015 - 2026) Analysis & Trends
Sunshine Biopharma (SBFM) has reported EBT Margin for 10 consecutive years, with 16.88% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EBT Margin rose 416.0% year-over-year to 16.88%; the trailing twelve-month figure through Jun 2026 stood at 15.73% (up 207.0% YoY), and the FY2025 full-year result was 16.4%, down 100.0% from the prior year.
- EBT Margin slipped to 16.88% in Q2 2026 per SBFM's latest filing, from 15.38% in the prior quarter.
- Across five years, EBT Margin topped out at 9.01% in Q2 2024 and bottomed at 1097.09% in Q3 2022.
- Historically, EBT Margin has averaged 182.55% across 5 years, with a median of 16.81% in 2024.
- The widest YoY moves for EBT Margin: up 1443245 bps in 2022, down 137462 bps in 2022.
- Over 5 years, EBT Margin stood at 590.86% in 2022, then jumped by 98 bps to 13.41% in 2023, then sank by 78 bps to 23.83% in 2024, then rose by 15 bps to 20.2% in 2025, then advanced by 16 bps to 16.88% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 16.88%, 15.38%, and 20.2% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.84 Bn | 39.19 Bn | 2.15 Bn | -10.99% |
| 2 | Viatris | 19.13 Bn | 18.24 Bn | 1.46 Bn | -1.70% |
| 3 | Dr Reddys Laboratories | 9.91 Bn | 9.74 Bn | 396.53 Mn | 6.85% |
| 4 | Amneal Pharmaceuticals | 5.51 Bn | 5.38 Bn | 334.51 Mn | 8.92% |
| 5 | Bausch Health Companies | 2.30 Bn | 464.50 Mn | 2.10 Bn | 12.20% |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | -121.92% |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | 13.94% |
| 8 | Amphastar Pharmaceuticals | 1.00 Bn | 714.13 Mn | 93.47 Mn | 20.96% |
| 9 | Fennec Pharmaceuticals | 402.10 Mn | 360.85 Mn | 17.15 Mn | 11.27% |
| 10 | Sunshine Biopharma | 1.55 Mn | -12.20 Mn | 2.43 Mn | -16.88% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -16.88% |
| Mar 31, 2026 | -15.38% |
| Dec 31, 2025 | -20.20% |
| Sep 30, 2025 | -10.84% |
| Jun 30, 2025 | -21.04% |
| Mar 31, 2025 | -13.71% |
| Dec 31, 2024 | -23.83% |
| Sep 30, 2024 | -11.65% |
| Jun 30, 2024 | -9.01% |
| Mar 31, 2024 | -16.73% |
| Dec 31, 2023 | -13.41% |
| Sep 30, 2023 | -10.25% |
| Jun 30, 2023 | -14.65% |
| Mar 31, 2023 | -33.84% |
| Dec 31, 2022 | -590.86% |
| Sep 30, 2022 | -1,097.09% |
| Jun 30, 2022 | -358.51% |
| Mar 31, 2022 | -1,007.98% |
| Dec 31, 2021 | 783.75% |
| Sep 30, 2021 | -8,018.47% |